Table 1

American College of Rheumatology core set components at baseline, week 4 and week 24 (last observation carried forward) in TNF antagonist-IR and DMARD-IR subgroups of patients

BaselineWeek 4Week 24
ComponentTNF antagonist-IRDMARD-IRTNF antagonist-IRDMARD-IRTNF antagonist-IRDMARD-IR
SJC/28 (n)12.3±8.413.3±7.36.6±5.96.2±7.13.8±4.93.0±4.9
TJC/28 (n)20.7±14.220.0±11.213.1±13.110.3±11.48.7±11.75.3±8.4
CRP (mg/l)26.7±28.620.7±32.27.1±17.24.5±12.82.7±4.33.3±9.5
ESR (mm/h)40.5±24.435.6±20.311.7±14.89.3±12.57.2±10.16.9±9.1
VAS physician disease activity (mm)64.6±16.661.2±19.438.1±23.827.9±20.223.9±23.213.2±14.9
VAS patient pain (mm)67.0±18.060.4±21.544.6±27.136.0±26.730.6±24.823.6±26.3
  • Data shown as mean±SD.

  • While there was no difference between patients pretreated with one or two TNF antagonists, patients with three TNF antagonists in the history showed a lesser response which, due to low numbers, was not statistically significant (data not shown)

  • CRP, C reactive protein; DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disease Index; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; TNF antagonist-IR, inadequate response to TNF antagonists; VAS, visual analogue scale.